Novartis | NVS - Equity Capital And Reserves

Stock Price
153.54
Daily Change
-0.41 -0.27%
Monthly
-6.50%
Yearly
36.69%
Q2 Forecast
150.15

Novartis reported $46.13B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Amgen USD 8.66B 961M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bausch Health Companies USD -554M 910M Dec/2025
Biogen USD 18.21B 573.5M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Canopy Growth CAD 758.17M 22.16M Dec/2025
Corcept Therapeutics USD 647.8M 15.9M Dec/2025
Drreddys Laboratories INR 4.14B 107.72M Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Glaxosmithkline GBP 22.06B 360M Dec/2025
J&J USD 78.47B 0 Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Novartis USD 46.13B 1.38B Dec/2025
Novartis USD 46.13B 1.8B Dec/2025
Pacira USD 693.11M 34.1M Dec/2025
Perrigo USD 2.94B 1.51B Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Phibro Animal Health USD 332.36M 20.68M Dec/2025
Prestige Brands USD 1.83B 4.48M Dec/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Supernus Pharmaceuticals USD 1.06B 12.05M Dec/2025
Zoetis USD 3.33B 2.07B Dec/2025